I don't believe that supply issues have anything to do with the hold up on approvals. Cytodyn with their 1.2 million vials had more on hand than any of the other drugs that received EUA. For example, when Regeneron was approved, they were only able to produce about 300,000 doses. Ely Lily's Bamlanvimab was approved and then took a full quarter to reach only 250,000 doses. After EUA approval, both of these companies received funding from the government to ramp up production. Regeneron is now producing about 2 million doses per year.

Samsung is one of the largest manufacturers in the world, and Nader confirmed on the last conference call that they are ready and willing to produce "millions" of doses per month . Still crickets from the U.S. so I am glad Cytodyn is pivoting to other countries. We just need $$$$ to get us going. Hopefully, these compassionate use sales will start coming in and we will be able to place larger and larger orders and help more people.